It's not about willpower — it's about biology
GLP-1 medications are FDA-approved, clinically proven, and work with your body's own hunger signals. No stimulants. No crash diets.
How dual GLP-1/GIP agonists work
Unlike older weight loss medications, GLP-1 agonists work with your body's natural hormone pathways — not against them.
Reduces appetite at the source
Activates GLP-1 receptors in the hypothalamus — your brain's appetite control center. Patients describe the constant mental chatter about food ("food noise") going quiet within days of starting treatment.
Slows gastric emptying
Delays how quickly food leaves your stomach, extending fullness after smaller meals. Dual-receptor activation amplifies this effect with significantly less nausea than older single-receptor GLP-1 medications.
Regulates blood sugar
Mimics the naturally-occurring GLP-1 hormone to improve insulin sensitivity and stabilize blood glucose. Reduces cravings for sugar and processed carbohydrates by preventing blood sugar spikes and crashes.
Preserves lean muscle mass
GIP receptor activation preferentially targets fat stores while protecting lean tissue. Patients retain 94% of lean mass — compared to older GLP-1s where up to 30% of weight lost was muscle, not fat.
Wondering if this medication is right for you? Free physician review takes 5 minutes.
Check my eligibility →Why dual GLP-1/GIP is the next generation
Single-receptor GLP-1 medications (like semaglutide) target only one pathway. Dual-agonists activate both GLP-1 and GIP receptors for superior results.
- 22.5% weight loss vs. 15.3% for single-receptor (NEJM data)
- 94% lean muscle retention vs. ~70% for older GLP-1s
- Lower nausea rates due to GIP buffering effect
- Improved cardiovascular markers
- Better sustained results at maintenance doses
- Once-weekly dosing — same convenience
Clinical trial results
NEJM, 2023: N=2,539. Dual GLP-1/GIP agonist achieved 22.5% total body weight loss over 72 weeks vs. 3.1% placebo.
The Lancet, 2023: N=1,800+. Body composition analysis showed 94% lean mass retention, significantly outperforming single-receptor protocols.
Individual results vary. Treatment prescribed only if clinically appropriate.
Side effects and safety information
Most side effects are mild, temporary, and resolve within the first few weeks of treatment.
Common side effects
Nausea — Most common in first 1-2 weeks, typically resolves. Manageable with dose titration.
Decreased appetite — Expected therapeutic effect.
Mild GI symptoms — Constipation or diarrhea in some patients, usually temporary.
Injection site reaction — Mild redness that resolves quickly.
Who should not take GLP-1s
Contraindicated for patients with:
• Personal/family history of medullary thyroid carcinoma or MEN 2 syndrome
• History of pancreatitis
• Pregnancy or breastfeeding
• Severe gastroparesis
• Type 1 diabetes
Your physician screens for all contraindications during review.
Medication questions
Related pages
Curious if GLP-1 treatment could work for you?
Take the free screening — a physician reviews your answers within 48 hours.
Take the free screening →